Pharmaceutical Technology

OCTOBER 5, 2022

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year.

Patients 111

Patients Safety Sales Manufacturing 111

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Pharmaceutical Technology

DECEMBER 16, 2022

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

Pharmaceutical Technology

DECEMBER 11, 2022

In the pirtobrutinib safety cohort, only 2.6% GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8 The mOS was 13.1 months, which in a historical context, is an improvement in the natural disease course of these patients. billion for Calquence.

FDA 59

FDA Patients Safety Pharmaceutical 59

European Pharmaceutical Review

NOVEMBER 1, 2023

While regulatory support, such as breakthrough therapy designations, can help in this regard, there is a critical need to collaborate with regulatory agencies to agree efficient clinical trial designs that maintain appropriate demonstration of safety and efficacy. AMR has the potential to be just as devastating for the world as COVID-19.

Safety 115

Safety Marketing Manufacturing Leads 115

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52